Express Pharma

Pacifab is reimagining encapsulation with first-of-its-kind formidable XTR

The pharma industry increasingly seeks solutions that integrate advanced capability and sustainability with cost-effectiveness and high ROI, and the XTR's hybrid encapsulation technology will revolutionise OSD manufacturing

0 489

Pacifab Technologies, a Mumbai-based provider of encapsulation solutions, has launched its high-end range of encapsulation machines called the XTR.

This machine promises exceptional production density with complete in-process control, precision and dosing flexibility at 60 per cent less footprint than standard machines.

The XTR is a formidable workhorse that encapsulates powder, pellets, tablets, micro tablets, liquids, capsules or soft gel in capsules, and removes the need for additional machinery. The advanced Null Gap System tamping technology pivots Pacifab to the cream of encapsulation technology globally, making it among the handful of companies that offer the best-in-class solutions even for hard-to-encapsulate products. It’s not the NGS that makes the XTR special, though. The machine packs several intentional and considered micro innovations and efficiencies to address often neglected encapsulation challenges and operator grievances and delivers a much higher yield than standard machines.

Vinod Sawant, Managing Director, Pacifab, and the brain behind these upgrades, said, “We’ve taken the industry standard and discarded it for a turbocharged racehorse. In designing the XTR, we did not want incremental innovation. So, we spent months talking to customers to understand their challenges and deliver a solution that addressed challenges in the boardroom and on the factory floor. What we have is a result of two years of active product development, and, as a team, we are proud of what we’re sending out to the industry.”

In 2015, Fabtech Technologies, followed three years later by Parle Global, invested in Pacifab to augment Pacifab’s native technological capabilities with their extensive domestic and international networks. The three-way partnership has resulted in indigenous encapsulation technology reaching all parts of the world.

Mahendra Mehta, Managing Director and Chief Executive Officer, Parle Global, thinks the XTR is India’s answer to high-end encapsulation. “I say with absolute confidence that there is no machine like this in the market at the moment. Vinod and his team have essentially rewritten the book on encapsulation technology and set the bar high. The XTR will fit right into any pharmaceutical manufacturing facility anywhere globally. Even in India, customers who have been importing because Indian versions weren’t able to offer the same controls now have a viable Made in India alternative.”

The XTR promises an exceptional price to performance ratio that is low on maintenance. You can seamlessly connect for downstream operations to our ancillary workhorses for a complete encapsulation solution.

Hemant Anavkar, Director, Fabtech Technologies, said, “We sell primarily to global markets where there is always the demand for the highest compliance. The XTR series underlines our indigenous technological prowess. While the XTR is our first encapsulation offering to disrupt the standard, we are proud we are the first to do it.”

When the ultimate goal is patient safety, every aspect has to meet the absolute highest standards. The XTR leaves standard encapsulation models behind with many times the control, agility and cost-benefit.

“This partnership of Pacifab with Parle and Fabtech is like a ring of confidence for customers. It underscores the technological capability, the global sales and support network and the assurance that we will always work harder to solve for our customers. This is only the beginning of many such innovations and industry-firsts to come,” said Aasif Khan, Chairman, Fabtech Group.

For more information, visit xtrbypacifab.com

- Advertisement -

Leave A Reply

Your email address will not be published.